Bio tech company updates — 11/21/2026
This health signal was created by a user. It may contain unverified medical claims. Always consult a qualified healthcare professional before making health decisions.
AstraZeneca Korea and Seoul Biohub selected Molcube and BuildGene for a 2026 global open-innovation program, while Curocell’s Limkato CAR-T therapy received a negotiated insurance price ceiling. The two reports cover startup support and a pending coverage decision, respectively.
Key Findings
- AstraZeneca Korea and Seoul Biohub selected Molcube and BuildGene for their 2026 Global Open Innovation program, which is intended to help Korean biotech and healthcare startups expand overseas.
- Curocell’s CAR-T therapy Limkato received a negotiated insurance price ceiling of 280,016,050 won, reported as about $210,071 and roughly 22% below Kymriah’s price. Coverage still requires a final health policy committee vote.
Details
AstraZeneca and Seoul Biohub select two startups
AstraZeneca Korea and Seoul Biohub chose Molcube and BuildGene for the 2026 Global Open Innovation program. The joint initiative is in its second year and aims to support Korean biotech and healthcare startups seeking to expand overseas.

Limkato receives negotiated price ceiling
Curocell’s Limkato received a negotiated insurance price ceiling of 280,016,050 won (about $210,071), approximately 22% below Kymriah, according to the report. A final health policy committee vote is still needed for coverage, which the report says is planned for December 1.

This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.